Other Events ·
PMV Pharmaceuticals announced updated interim data from the Phase 2 pivotal PYNNACLE trial for its p53 reactivator…
PMVPPMV Pharmaceuticals, Inc.
PMV Pharmaceuticals announced updated interim data from the Phase 2 pivotal PYNNACLE trial for its p53 reactivator rezatapopt in platinum-resistant/refractory ovarian cancer. Among 76 evaluable patients, the drug demonstrated a 46% overall response rate with a median duration of response of 10.0 months and a favorable safety profile. The company received FDA feedback supporting a New Drug Application strategy for accelerated approval, with submission planned for the first quarter of 2027. PMV Pharmaceuticals is a precision oncology company developing small molecule therapies targeting p53 mutations.